Cargando…
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma
PURPOSE: Malignant pleural mesothelioma (MPM) is a rare malignancy with a dismal median survival of <12 months with current therapy. Single and combination chemotherapy regimens have shown only modest clinical benefit. In preclinical studies, nitrogen-containing bisphosphonates (zoledronic acid)...
Autores principales: | Jamil, Muhammad Omer, Jerome, Mary S, Miley, Deborah, Selander, Katri S, Robert, Francisco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5476579/ https://www.ncbi.nlm.nih.gov/pubmed/28652837 http://dx.doi.org/10.2147/LCTT.S135802 |
Ejemplares similares
-
Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
por: Salaroglio, Iris Chiara, et al.
Publicado: (2014) -
Advances in Immunotherapy of Malignant Pleural Mesothelioma
por: Liao, Dongying, et al.
Publicado: (2021) -
Malignant pleural mesothelioma
por: Rao, Sukhesh
Publicado: (2009) -
Malignant pleural mesothelioma with resolution of pleural effusion
por: Nishida, Sayaka, et al.
Publicado: (2023) -
Malignant pleural mesothelioma in Italy
por: Bianchi, Claudio, et al.
Publicado: (2009)